Mireille H. Snel

Science Park
Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.

Journal: Communications biology
Published: January 03, 2020

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.

Journal: Translational oncology
Published: October 08, 2019

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

Journal: Translational oncology
Published: June 27, 2019

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

Journal: High-throughput
Published: October 12, 2017

A breast cancer gene signature for indolent disease.

A breast cancer gene signature for indolent disease.

Journal: Breast cancer research and treatment
Published: March 31, 2017

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Journal: Biomarker insights
Published: August 21, 2016

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Journal: Breast cancer research and treatment
Published: March 16, 2016

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Journal: Scientific reports
Published: July 23, 2015

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.

Journal: International journal of cancer
Published: June 14, 2013

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

Journal: Annals of surgery
Published: January 09, 2013

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

Journal: Gut
Published: July 17, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026